THE CORPORATE REPUTATION OF THE PHARMA INDUSTRY IN 2015: THE PERSPECTIVE OF PATIENT GROUPS WITH AN INTEREST IN ...

SKIN CONDITIONS

(1st edition)

Report published by PatientView, May 2016

If you would like more information, or would like to get hold of this report, please use contact details below

• Contact: Alex Wyke

• Tel: +44-(0)1547-520-965

• Email: report@patient-view.com

• Website: http://www.patient-view.com

• Publication date:  Monday, May 9th, 2016

About this report

London, May 9th, 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 110 patient groups worldwide with an interest in skin conditions. The report provides feedback (from the perspective of  patient groups with an interest in skin conditions) on the corporate reputation of the pharma industry during 2015, as well as on the performance of 20 pharma companies for six key indicators that influence corporate reputation. Results are compared with those of other therapy areas from the 2015 survey.

For the purposes of this report, the phrase ‘corporate reputation’ is defined as the extent to which pharma companies are meeting the expectations of patients and patient groups.

In this 2015 series of ‘Corporate Reputation of Pharma’ reports, PatientView gave pharma companies the opportunity to tell their own story about their 2015 patient-centric strategies and activities in the field of patient-group relations. In each of the regional reports in the 2015 ‘Corporate Reputation’ series, we will feature, as case studies, the full responses of at least one company. In this report, one company is featured:  LEO Pharma. 

The six indicators of corporate reputation:

1. Patient-centricity.
2. Patient information.
3. Patient safety.
4. Useful products.
5. Transparency.  And ...
6. Integrity.

The 20 companies analysed:

AbbVie I Actavis I Amgen I AstraZeneca I Bayer I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I GSK I Janssen I Leo Pharma I Lilly I Merck & Co I Novartis I Pfizer I Roche I Sandoz I Sanofi I Teva I UCB

“ Pharma companies have become more active, and willing to participate in patient-oriented activities.”

—National Hong Kong-based patient
group with an interest in psoriasis

“The sector must be in better touch with patients.”

—National Turkey-based patient group with an interest in psoriasis

INDUSTRY-WIDE FINDINGS

45.1% of the 110 patient groups specialising in skin conditions and respondent to the 2015 ‘Corporate Reputation of Pharma’ survey stated that the pharma industry as a whole had an “Excellent” or “Good” corporate reputation that year. The equivalent figure for patient groups from all therapy areas in 2015 was 44.7%. Patient groups specialising in skin conditions responding in 2015 ranked the pharma industry 5th out of 8 healthcare-industry sectors for corporate reputation—ahead of generics, for-profit health insurers, and not-for-profit health insurers. Pharma also ranked 5th in 2015's global therapy-wide results.

In 2015, the pharma industry received positive responses for several of its key activities from the 110 patient groups specialising in skin conditions:

• As many as 62% of the patient groups with an interest in skin conditions responding to the 2015 ‘Corporate Reputation of Pharma’ survey described the industry as a whole as “Excellent” or “Good” at patient safety—a higher figure than from patient groups of any other therapy area (bar diabetes). The equivalent figure from patient groups across all therapy areas in 2015 was 58%.
• As many as 52% of the patient groups with an interest in skin conditions responding to the 2015 ‘Corporate Reputation of Pharma’ survey described the industry as a whole as “Excellent” or “Good” at providing high-quality patient information—again, a higher figure than from patient groups of any other therapy area (the figure from patient groups across all therapy areas in 2015 was 48%).

The percentage of skin patient groups (compared with patient groups from other therapy areas) stating that pharma in 2015 was “Excellent” or “Good” at ensuring PATIENT SAFETY

However ...

Patient groups with an interest in skin conditions retain reservations about some of the pharma industry’s activities.

Only 12% of patient groups specialising in skin conditions and responding in 2015 thought pharma “Excellent” or “Good” at having fair pricing policies. The equivalent figure among patient groups from all therapy areas in 2015 was 15%. Pricing remains the most divisive issue separating most types of patient groups and pharma.

The percentage of skin patient groups (compared with patient groups from other therapy areas) stating that pharma in 2015 was “Excellent” or “Good” at HAVING FAIR PRICING POLICIES

HOW COMPANIES PERFORMED FOR CORPORATE REPUTATION IN 2015: SKIN

Patient groups which stated that they had an interest in skin conditions were diverse in specialty, and included those which concentrated on ...

• Allergy
• Autoimmune conditions
• Burns
• Eczema
• Lupus
• Psoriasis
• Rare skin conditions
• Rheumatological conditions
• Skin cancer

Worth noting is that Leo Pharma ranks overall 2nd among the 20 pharma companies assessed in this 2015 skin report. Leo’s product line mainly focuses on skin conditions. Pharma companies that sit at the top (or near the top of) the league tables for corporate reputation, as ranked by patient groups, often concentrate on (or invest heavily in) specific disease areas.

What are your company’s plans for improving its PAG relations, its patient advocacy, or its patient centricity in 2016 (from your perspective)?

Extract from response by Leo Pharma to PatientView pharma survey 2015

"In 2016, LEO Pharma will:  * Meet its goal, six months earlier than planned, for publishing clinical-study reports, and summaries for trials dating back to 1990.  * We will engage patients in our clinical-development programme in a number of ways, with a view to tailoring our drug development to better meet patient needs. One example is that we will engage with patient associations to seek advice on protocol development. Our first engagement will be with the National Psoriasis Foundation in the US in March.  * Continue to give patients a key role in roundtable debates where LEO Pharma is involved. Topics span issues such as health-technology assessment (HTA) and patient involvement in Europe, debates about skin-cancer prevention, and unmet needs in dermatology epidemiology studies.”

END OF STATEMENT

PatientView is a UK-based research organisation that consults closely with patient groups, and publicises the work of the patient-advocacy movement.